In the News

BioSpace: OncoResponse IDs Elite Cancer Responders’ Antibodies to Make IO More Effective

Business Wire: Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse

AACR Journals: Abstract 1719: OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression caused by tumor associated macrophages

AACR Journals: Abstract 1638: Discovery and preclinical characterization of anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression

GeekWire: Seattle biotech OncoResponse raises $40.6M to create antibody-based treatments for cancer

Contract Pharma: Just - Evotec, OncoResponse Enter Antibody Alliance

BioWorld: OncoResponse completes $40M series B, shifting from discovery to development

ENDPOINTS: Focusing on the tumor microenvironment, OncoResponse garners $40 million for the next stage of the R&D journey

BioCentury: OncoResponse moves into clinic with $40M series B

FierceBiotech: OncoResponse raises $40M for cancer patient-sourced antibodies

Xconomy: OncoResponse Nabs $40M for Cancer Drugs Based On Survivors’ Antibodies

Puget Sound Business Journal: Theraclone venture OncoResponse reports $29.5M in funding

BioCentury: Emerging Company Profile: Interrogating Immunity

BioWorld: Theraclone, MD Anderson target super-responders in IO start-up

Xconomy: Houston’s M.D. Anderson, Theraclone Launch Immunotherapy Startup

FierceBiotech: Hub-building MD Anderson partners with Theraclone on $9.5M biotech startup

GEN: MD Anderson, Theraclone Launch Immuno-Oncology Antibody Discovery Company